<DOC>
	<DOCNO>NCT02283268</DOCNO>
	<brief_summary>The purpose study assess efficacy safety recombinant von Willebrand factor ( rVWF ) without ADVATE major minor elective surgical procedure adult patient hereditary severe von Willebrand disease ( VWD ) .</brief_summary>
	<brief_title>Recombinant Von Willebrand Factor Subjects With Severe Von Willebrand Disease Undergoing Surgery</brief_title>
	<detailed_description />
	<mesh_term>Von Willebrand Diseases</mesh_term>
	<criteria>Diagnosis severe von Willebrand disease ( VWD ) list elective surgical procedure plan 1 . Type 1 ( Von Willebrand factor : Ristocetin cofactor activity ( VWF : RCo ) &lt; 20 IU/dL ) , 2 . Type 2A ( verified multimer pattern ) , Type 2B ( diagnose genotype ) , Type 2N ( FVIII : C &lt; 10 % historically document genetics ) , Type 2M , 3 . Type 3 ( Von Willebrand factor antigen ( VWF : Ag ) ≤ 3 IU/dL ) VWD history require substitution therapy von Willebrand factor ( VWF ) concentrate control bleed If type 3 VWD ( VWF Antigen /VWF : Ag ≤ 3 IU/dL ) , participant medical history least 20 exposure day VWF/FVIII coagulation factor concentrate ( include cryoprecipitate fresh frozen plasma ) If type 1 type 2 VWD , participant medical history 5 exposure day past major surgery require VWF/FVIII coagulation factor concentrate ( include cryoprecipitate fresh frozen plasma ) Participant least 18 year age If female childbearing potential , participant present negative pregnancy test If applicable , participant agree employ adequate birth control measure duration study Participant willing able comply requirement protocol Diagnosis pseudo VWD another hereditary acquire coagulation disorder ( eg , qualitative quantitative platelet disorder elevate prothrombin time [ PT ] / international normalize ratio [ INR ] &gt; 1.4 ) History presence VWF inhibitor screen History presence factor VIII ( FVIII ) inhibitor titer ≥ 0.4 BU ( Nijmegenmodified Bethesda assay ) ≥ 0.6 BU ( Bethesda assay ) Known hypersensitivity component study drug , mouse hamster proteins Medical history immunological disorder , exclude seasonal allergic rhinitis/conjunctivitis , mild asthma , food allergy animal allergy Medical history thromboembolic event HIV positive absolute CD4 count &lt; 200/mm3 Platelet count &lt; 100,000/mL Diagnosis significant liver disease , evidence , limited , follow : serum alanine aminotransferase ( ALT ) 5 time upper limit normal ; hypoalbuminemia ; portal vein hypertension ( eg . presence otherwise unexplained splenomegaly , history esophageal varix ) liver cirrhosis classify Child B C Diagnosis renal disease , serum creatinine level ≥ 2 .5mg/dL Participant treat immunomodulatory drug , exclude topical treatment ( eg , ointment , nasal spray ) , within 30 day prior sign inform consent Participant pregnant lactating time inform content obtain Participant participate another clinical study involve investigational product ( IP ) , rVWF without ADVATE , investigational device within 30 day prior enrollment schedule participate another clinical study involve IP investigational device course study . However , eligible patient participate rVWF Prophylaxis Study ( 071301 ) may enrol . Progressive fatal disease and/or life expectancy le 3 month Participant identify investigator unable unwilling cooperate study procedure Participant suffers mental condition render him/her unable understand nature , scope possible consequence study and/or evidence uncooperative attitude Participant prison compulsory detention regulatory and/or juridical order Participant member study team conduct study dependent relationship one study team member . Dependent relationship include close relative ( ie , child , partner/spouse , sibling , parent ) well employee .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>